Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme

BACKGROUND: Cabazitaxel is a second-generation taxane approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. Early access programmes were established to allow eligible patients with mCRPC access to cabazitaxel before regulatory ap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Malik, Zafar, Heidenreich, Axel, Bracarda, Sergio, Ardavanis, Alexandros, Parente, Philip, Scholz, Hans-Joerg, Ozatilgan, Ayse, Ecstein-Fraisse, Evelyne, Hitier, Simon, Di Lorenzo, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6609246/
https://ncbi.nlm.nih.gov/pubmed/31289614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados